Fundraising Fox

Biocartis

Mechelen, BE · 4 known investors

Biocartis develops molecular diagnostic testing systems for cancer, with a focus on enabling personalized medicine through rapid, in-house biomarker analysis. The company's Idylla Platform automates molecular testing to help clinicians and patients access treatment information quickly.

BiotechDigital HealthHealthtechMedical Devices

Investors · 4

Advent Life SciencesLondon
KorysHalle · $5.4M
New Rhein Healthcare Investors, LLCPhiladelphia
PMVBrussels

In the news

Biocartis Successful IPO - The Start of a New Era - Debiopharmdebiopharm.com · May 2015Belgium's Biocartis raises 100 mln euros in stock market debut | Reutersreuters.com · Apr 2015Biocartis Raises EUR 100 Million In Successful IPO - BioSpacebiospace.com · Apr 2015BioCentury - Biocartis raises EUR 30 million in series Ebiocentury.com · Nov 2013Biocartis Completes €34,5M Series D Equity Funding - FinSMEsfinsmes.com · Dec 2012Biocartis Raises EUR10 Million in Series A Financing Round | Fierce Biotechfiercebiotech.com · Oct 2009

Frequently asked questions

What does Biocartis do?
Biocartis develops molecular diagnostic testing systems for cancer, with a focus on enabling personalized medicine through rapid, in-house biomarker analysis. The company's Idylla Platform automates molecular testing to help clinicians and patients access treatment information quickly.
Who are Biocartis's investors?
Biocartis's investors include Advent Life Sciences, Korys, New Rhein Healthcare Investors, LLC, PMV.
Where is Biocartis headquartered?
Biocartis is headquartered in Mechelen, BE.